GLENMARK PHARMACEUTICALS EUROPE LIMITED

Glenmark Pharmaceuticals has launched Tevimbra (tislelizumab), marking the company's first entry into immuno-oncology in India following CDSCO approval.

Glenmark Pharmaceuticals has received DCGI approval to launch zanubrutinib (BRUKINSA) in India, marking the first BTK inhibitor approved for treating five distinct B-cell malignancies.

Glenmark Pharmaceuticals will launch a generic version of Adderall tablets in five dosage strengths starting May 2025, providing a bioequivalent alternative to the reference drug by Teva Women's Health.

Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in three dosage strengths: 750 mg, 1.25 g, and 1.5 g single-dose vials.

Glenmark Therapeutics has launched Polyethylene Glycol 3350 powder (17 grams/capful) as an over-the-counter constipation treatment in the US market, comparable to MiraLAX®.

Glenmark Pharmaceuticals has acquired and launched Acetylcysteine Injection (6 gm/30 mL) in the US market, expanding its presence in the hospital segment through the ANDA acquisition from Aspen Pharma USA.

Glenmark Pharmaceuticals has initiated a recall of approximately 1.5 million bottles of an ADHD medication from the US market following FDA oversight.

Glenmark Pharmaceuticals has launched a generic version of Epinephrine Injection USP (10 mg/10 mL) Multiple-Dose Vial, securing 180 days of competitive generic therapy exclusivity.

• Mankind Pharma has developed a pioneering GPR109 agonist as the world's first potential small-molecule oral treatment for obesity, currently advancing through Phase 2 trials in Australia. • The innovative drug offers advantages over existing injectable peptide treatments like Wegovy and Mounjaro, requiring no food-related restrictions and providing a more convenient oral administration route. • Phase 1 results have shown promising outcomes, with Phase 2 trial results expected by the end of the year, positioning Mankind Pharma for a potential breakthrough in the global obesity treatment market.

• Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust lawsuits with three major healthcare entities - Humana, Centene, and Kaiser - over generic cholesterol medications Zetia and Vytorin. • The lawsuits alleged that Glenmark entered an anticompetitive agreement in 2010 with Schering Corporation and MSP Singapore Company LLC regarding patent infringement litigation for ezetimibe. • While reaching the settlement agreement, Glenmark explicitly denies all allegations and maintains the settlement does not indicate any admission of liability or illegal conduct.